BioNTech Reconciled Depreciation from 2010 to 2024

BNTX Stock  USD 118.54  2.22  1.84%   
BioNTech Reconciled Depreciation yearly trend continues to be fairly stable with very little volatility. Reconciled Depreciation is likely to outpace its year average in 2024. During the period from 2010 to 2024, BioNTech Reconciled Depreciation regression line of annual values had r-squared of  0.66 and arithmetic mean of  50,221,733. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2018-09-30
Previous Quarter
49.9 M
Current Value
44.4 M
Quarterly Volatility
17.7 M
 
Covid
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many indicators such as Price To Sales Ratio of 5.77, Dividend Yield of 0.0111 or PTB Ratio of 1.2. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
  
Check out the analysis of BioNTech Correlation against competitors.

Latest BioNTech's Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of BioNTech SE over the last few years. It is BioNTech's Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

BioNTech Reconciled Depreciation Regression Statistics

Arithmetic Mean50,221,733
Geometric Mean25,722,610
Coefficient Of Variation127.90
Mean Deviation49,811,076
Median10,529,000
Standard Deviation64,233,708
Sample Variance4126T
Range182M
R-Value0.81
Mean Square Error1493.4T
R-Squared0.66
Significance0.0002
Slope11,703,164
Total Sum of Squares57763.6T

BioNTech Reconciled Depreciation History

2024192.6 M
2023183.4 M
2022123.3 M
202175.2 M
202038.7 M
201933.9 M
201822 M

About BioNTech Financial Statements

BioNTech investors use historical fundamental indicators, such as BioNTech's Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation183.4 M192.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.